Leatt Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Leatt Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.91M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $44.03M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $47.24M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $76.34M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $72.48M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $38.60M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $28.32M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $24.39M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $20.14M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $16.42M | Mar 27, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.22M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $17.71M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $19.81M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $31.13M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $31.45M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $17.39M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $13.01M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $11.57M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $9.47M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $8.24M | Mar 27, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.26M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($2.20M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $803.2K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $9.96M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $12.57M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $4.42M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.38M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.20M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $237.3K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($455.2K) | Mar 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.01M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | ($2.98M) | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.42M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $13.02M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $16.62M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $5.84M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.98M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.49M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $225.5K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | ($731.7K) | Mar 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.70M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.52M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $2.53M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.18M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $1.83M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.52M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.49M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.41M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $1.36M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $1.44M | Mar 27, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.79M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $6.66M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $3.09M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $2.78M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.35M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $845.6K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.14M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $1.72M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $320.2K | Mar 27, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.05M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $46.49M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $47.61M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $51.93M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $49.17M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $26.24M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $18.19M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $12.74M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $12.79M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $10.78M | Mar 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.81M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $8.22M | Mar 24, 2026 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.23M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $38.26M | Mar 24, 2026 |
| FY2025 | Dec 31, 2023 | $40.28M | Mar 24, 2026 |
| FY2024 | Dec 31, 2022 | $39.69M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $28.62M | Mar 13, 2024 |
| FY2022 | Dec 31, 2020 | $15.37M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $10.72M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $9.05M | Mar 24, 2021 |
| FY2019 | Dec 31, 2017 | $7.80M | Mar 24, 2020 |
| FY2018 | Dec 31, 2016 | $7.22M | Mar 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.86M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $28.60M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $30.80M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $30.00M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $20.04M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $7.46M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $3.04M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.66M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $465.4K | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | $228.1K | Mar 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.99M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | $12.37M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | $11.35M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $7.10M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $5.02M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $2.97M | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $2.07M | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $1.71M | Mar 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.52M | Mar 24, 2020 |
| FY2018 | Dec 31, 2016 | $1.10M | Mar 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.8K | Mar 24, 2026 |
| FY2024 | Dec 31, 2024 | $30.5K | Mar 28, 2025 |
| FY2023 | Dec 31, 2023 | $143.5K | Mar 13, 2024 |
| FY2022 | Dec 31, 2022 | $250.4K | Mar 28, 2023 |
| FY2021 | Dec 31, 2021 | $272.5K | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 2 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 27, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 1 | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 2 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 27, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.23M | Mar 24, 2026 |
| FY2025 | Dec 31, 2024 | 6.22M | Mar 24, 2026 |
| FY2024 | Dec 31, 2023 | 6.22M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 5.97M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 5.67M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 5.43M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 5.39M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 5.37M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | 5.37M | Mar 27, 2019 |
| FY2017 | Dec 31, 2016 | 5.36M | Mar 27, 2018 |